HTBX - Heat Biologics, Inc.
| Previous Close | 1.4200 |
| Open | 1.4300 |
| Bid | 1.45 x 1000 |
| Ask | 1.52 x 800 |
| Day's Range | 1.4000 - 1.4997 |
| 52 Week Range | 0.9500 - 4.3000 |
| Volume | 888,109 |
| Avg. Volume | 487,978 |
| Market Cap | 47.063M |
| Beta (3Y Monthly) | 2.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 |
| Earnings Date | Feb 28, 2019 - Mar 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
- Simply Wall St.•5 days ago
What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Heat Biologics, Inc. (NASDAQ:HTBX)Read More...
- ACCESSWIRE•last month
UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).
- ACCESSWIRE•last month
Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported earlier this year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).
- Benzinga•last month
The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9: China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...
- ACCESSWIRE•last month
Heat Biologics Provides Clinical and Business Update
DURHAM, NC / ACCESSWIRE / January 10, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today provided a business update regarding the company's progress and plans for 2019. Jeff Wolf, Heat's CEO, commented, "We have postponed reporting our most recent interim data to enable us to present this data at a leading oncology conference.
- ACCESSWIRE•last month
Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
DURHAM, NC / ACCESSWIRE / January 8, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that the Company's principal investigator for its Phase 2 Lung Cancer Trial, Daniel Morgensztern, MD, Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine, has been selected to deliver an oral presentation of his abstract summarizing new interim data from the Company's Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), in patients with advanced non-small cell lung cancer (NSCLC) at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The 2019 ASCO-SITC Clinical Immuno-Oncology Symposium will be held from February 28-March 2, 2019 at the San Francisco Marriott Marquis.
- ACCESSWIRE•last month
Heat Biologics to Present at Biotech Showcase 2019 in California
DURHAM, NC / ACCESSWIRE / January 4, 2019 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that it will be presenting at the Biotech Showcase 2019 conference on Tuesday, January 8, 2019, at 11:30 a.m. PST in the Yosemite C ballroom at the Hilton San Francisco Union Square. Jeff Wolf, CEO of Heat Biologics, will be presenting. Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells.
- Zacks Small Cap Research•3 months ago
HTBX: Plenty of Catalysts in 2019
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Third Quarter 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2018 results in an August 14th release and ...
- American City Business Journals•3 months ago
Durham company rakes in another $13.8M through public offering
Heat Biologics just banked an additional $13.8 million in its latest public offering. The Durham-based biopharmaceutical company (Nasdaq: HTBX) announced the public offering last week. It estimated the gross proceeds from the offering to come close to $12 million. At close on Monday, that figure realized an additional $1.8 million.
- ACCESSWIRE•3 months ago
Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering
DURHAM, NC / ACCESSWIRE / November 26, 2018 / Heat Biologics, Inc. (''Heat'') (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock together with warrants to purchase 4,000,000 shares of its common stock at a combined price to the public of $1.50. In addition, the underwriter exercised the over-allotment option to purchase an additional 1,200,000 shares of common stock and warrants to purchase 600,000 shares of common stock. Gross proceeds to Heat from this offering are approximately $13,800,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Heat.
- ACCESSWIRE•3 months ago
Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum
DURHAM, NC / ACCESSWIRE / November 26, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today ...
- GlobeNewswire•3 months ago
Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- TheStreet.com•3 months ago
Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
The North Carolina-based biopharmaceutical company expected to offer 8 million shares of common stock and warrants to purchase 4 million shares of common stock with an expected combined price of $1.50. The money raised would be used to further develop its so-called T-cell immunotherapies that if successful would activate a patient's immune system to fight off cancer. , a London-based clinical-stage biopharmaceutical company, slipped 1.76% to $7.82, while New York-based Axsome Therapeutics, Inc.
- Simply Wall St.•3 months ago
Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Historical Volatility?
If you own shares in Heat Biologics Inc (NASDAQ:HTBX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Benzinga•3 months ago
The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...
- ACCESSWIRE•3 months ago
Heat Biologics, Inc. Prices $12,000,000 Public Offering
DURHAM, NC / ACCESSWIRE / November 21, 2018 / Heat Biologics, Inc. ("Heat") (HTBX), a biopharmaceutical company developing immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation, today announced the pricing of an underwritten public offering consisting of 8,000,000 shares of Common Stock together with Warrants to purchase 4,000,000 shares of Common Stock at a combined price to the public of $1.50. Heat Biologics, Inc. has granted the underwriter a 45-day option to purchase additional shares of Common Stock and/or additional Warrants to cover over-allotments, if any.
- ACCESSWIRE•3 months ago
Heat Biologics, Inc. Announces Proposed Public Offering
DURHAM, NC / ACCESSWIRE / November 20, 2018 / HEATBIOLOGICS, INC. (HTBX), a biopharmaceutical company developing immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation, today announced that it intends to offer for sale its common stock and warrants to purchase shares of its common stock in an underwritten public offering. Heat Biologics, Inc. intends to use the net proceeds from this offering to fund, among other things, its and its subsidiaries' preclinical and clinical programs and for working capital and general corporate purposes, including, to acquire, license or invest in complementary businesses, technologies, product candidates or other intellectual property. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.
- ACCESSWIRE•3 months ago
Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update
On track to report key clinical milestones beginning in Q4 2018 DURHAM,NC / ACCESSWIRE / November 15, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed ...
- ACCESSWIRE•4 months ago
Heat Biologics to Present at Precision: Lung Cancer World R&D Summit
DURHAM, NC /ACCESSWIRE / October 22, 2018 / HeatBiologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced ...
- ACCESSWIRE•4 months ago
Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City
DURHAM, NC / ACCESSWIRE / October 19, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced ...
- ACCESSWIRE•4 months ago
Heat Biologics to Present at the 2018 BIO Investor Forum
DURHAM, NC / ACCESSWIRE / October 10, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced ...
- ACCESSWIRE•5 months ago
Heat Biologics’ Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator
DURHAM, NC / ACCESSWIRE / October 4, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, and its Pelican Therapeutics subsidiary ("Pelican") today provided a progress update on its novel PTX-35 co-stimulatory antibody. When combined with immunotherapies, including checkpoint inhibitors as well as Heat's ImPACT® and ComPACT™ technologies, PTX-35 has been shown to enhance antigen-specific T-cell activation to eliminate tumor cells in pre-clinical models.
- Simply Wall St.•5 months ago
What does Heat Biologics Inc’s (NASDAQ:HTBX) Balance Sheet Tell Us About Its Future?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Heat Biologics Inc (NASDAQ:HTBX), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
- Zacks Small Cap Research•6 months ago
HTBX: Multiple Milestones on the Horizon
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Second Quarter 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported second quarter 2018 results in an August 14th release and ...
- ACCESSWIRE•6 months ago
Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City
DURHAM, NC / ACCESSWIRE / August 29, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced ...
